{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:15:07Z","timestamp":1784675707581,"version":"3.55.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>CITE was a prospective, noninterventional study in adult patients with chronic immune thrombocytopenia treated with eltrombopag under routine clinical care in Asia-Pacific, the Middle East, and Turkey. Data to assess eltrombopag usage, compliance, and outcomes were collected from May 2017 to December 2020. Platelet response was defined as platelet count \u226550\u00a0\u00d7 103\/\u03bcL in the absence of rescue medications and splenectomy. Quality of life was evaluated using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire. Noncompliance was defined as the number of missed doses and number of days where the patient did not follow food instructions. A total of 231 patients were enrolled; the median (range) duration of eltrombopag treatment was 484.5 (1-642) days. Compliance to prescribed eltrombopag dose since the previous routine visit was high at \u226596.0%. Baseline median platelet count was 19.0\u00a0\u00d7 103\/\u03bcL, which increased to \u226550\u00a0\u00d7 103\/\u03bcL at month 2 and mostly fluctuated between 70\u00a0\u00d7 103\/\u03bcL and 100\u00a0\u00d7 103\/\u03bcL thereafter. The median time to first platelet response was 1.05 (95% confidence interval: 0.92-1.28) months, and the median (interquartile range) maximum duration of platelet response was 193 (57-456) days. FACIT-F scores improved from a mean (standard deviation) 34.4 (12.1) at baseline to 38.5 (9.1) at month 18. Adverse events occurred in 50.9% of patients (n\u00a0= 116), the most common being upper respiratory tract infection (8.3%) and headache (6.6%). These findings confirmed the effectiveness of eltrombopag treatment in routine practice and reassured that real-world compliance to eltrombopag-prescribed doses and dietary instructions in Asia-Pacific, the Middle East, and Turkey were in line with current recommendations.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008287","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T16:58:03Z","timestamp":1663174683000},"page":"4773-4781","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9011-4268","authenticated-orcid":false,"given":"Raymond Siu Ming","family":"Wong","sequence":"first","affiliation":[{"name":"1Sir Y.K. Pao Centre for Cancer and Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1703-2175","authenticated-orcid":false,"given":"\u0130rfan","family":"Yava\u015fo\u011flu","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Faculty of Medicine, Adnan Menderes University, Ayd\u0131n, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"3National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar","family":"Tarkun","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Medical Faculty, Kocaeli University, Kocaeli, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-7459","authenticated-orcid":false,"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie","family":"Wei","sequence":"additional","affiliation":[{"name":"6The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8841-048X","authenticated-orcid":false,"given":"Ashraf","family":"Elghandour","sequence":"additional","affiliation":[{"name":"7Faculty of Medicine, Alexandria University, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantep","family":"Angchaisuksiri","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Ozcan","sequence":"additional","affiliation":[{"name":"9Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renchi","family":"Yang","sequence":"additional","affiliation":[{"name":"10Institute of Haematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervat","family":"Mattar","sequence":"additional","affiliation":[{"name":"11Clinical Hematology Unit, Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masiur","family":"Rahman","sequence":"additional","affiliation":[{"name":"12Novartis Oncology, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ingles","sequence":"additional","affiliation":[{"name":"12Novartis Oncology, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Goldbrunner","sequence":"additional","affiliation":[{"name":"12Novartis Oncology, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Frueh","sequence":"additional","affiliation":[{"name":"12Novartis Oncology, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-4676","authenticated-orcid":false,"given":"Jun Ho","family":"Jang","sequence":"additional","affiliation":[{"name":"13Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"issue":"S1","key":"2023091114543372500_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.HS9.0000561088.53023.c9","article-title":"PF701 assessment of eltrombopag in patients with chronic immune thrombocytopenia under routine clinical practice in the Middle East, Turkey, Asia, and Australia","volume":"3","author":"Wong","year":"2019","journal-title":"HemaSphere"},{"key":"2023091114543372500_bib2","unstructured":"Wong\n              R\n            , Yava\u015fo\u011flu\u0130, YassinM, . Eltrombopag in patients with chronic ITP under routine clinical practice in the middle East, Asia (East and South), and Australia: an interim analysis of the CITE study. Accessed 6 October 2021. https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/294129\/raymond.wong.eltrombopag.in.patients.with.chronic.itp.under.routine.clinical.html."},{"issue":"6","key":"2023091114543372500_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/2042098618769587","article-title":"Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety","volume":"9","author":"Gonzalez-Porras","year":"2018","journal-title":"Ther Adv Drug Saf"},{"issue":"9664","key":"2023091114543372500_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"issue":"9763","key":"2023091114543372500_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"issue":"23","key":"2023091114543372500_bib6","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2023091114543372500_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ejh.12725","article-title":"Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice","volume":"97","author":"Gonzalez-Lopez","year":"2016","journal-title":"Eur J Haematol"},{"issue":"22","key":"2023091114543372500_bib8","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"Suppl 5","key":"2023091114543372500_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000492187","article-title":"Immune thrombocytopenia - current diagnostics and therapy: recommendations of a Joint Working Group of DGHO, OGHO, SGH, GPOH, and DGTI","volume":"41","author":"Matzdorff","year":"2018","journal-title":"Oncol Res Treat"},{"issue":"10","key":"2023091114543372500_bib10","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s11136-011-9912-9","article-title":"Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia","volume":"20","author":"Signorovitch","year":"2011","journal-title":"Qual Life Res"},{"issue":"1","key":"2023091114543372500_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MBC.0000000000000380","article-title":"Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study","volume":"27","author":"Eser","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"2023091114543372500_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00277-015-2556-z","article-title":"The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a \"real life\" retrospective multicenter experience of the Rete Ematologica Pugliese (REP)","volume":"95","author":"Mazza","year":"2016","journal-title":"Ann Hematol"},{"issue":"S1","key":"2023091114543372500_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-139967","article-title":"Eltrombopag for immune thrombocytopenia in adult patients in the real-world in France. Final results of the Elextra study","volume":"136","author":"Moulis","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2023091114543372500_bib14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2217\/cer-2019-0177","article-title":"Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists","volume":"9","author":"Forsythe","year":"2020","journal-title":"J\u00a0Comp Eff Res"},{"key":"2023091114543372500_bib15","article-title":"Evaluation of treatment patterns among patients with newly diagnosed, persistent, and chronic immune thrombocytopenia (ITP) treated with eltrombopag in real world setting in the US","volume":"130","author":"Stafkey-Mailey","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2023091114543372500_bib16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07615.x","article-title":"Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database","volume":"145","author":"Schoonen","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"2023091114543372500_bib17","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1538-7836.2006.02147.x","article-title":"Prevalence of immune thrombocytopenia: analyses of administrative data","volume":"4","author":"Segal","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"2023091114543372500_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.24702","article-title":"Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort","volume":"92","author":"Moulis","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"2023091114543372500_bib19","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"23","key":"2023091114543372500_bib20","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2023091114543372500_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","article-title":"Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales","volume":"24","author":"Cella","year":"2002","journal-title":"J\u00a0Pain Symptom Manage"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4773\/2077062\/blooda_adv-2022-008287-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/17\/4773\/2077062\/blooda_adv-2022-008287-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T14:55:39Z","timestamp":1694444139000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/17\/4773\/486586\/Eltrombopag-in-patients-with-chronic-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":21,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008287","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}